Entering text into the input field will update the search result below

Aastrom (ASTM) Drops CLI Program Focus On Dilated Cardiomyopathy

Mar. 27, 2013 9:31 AM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Strategic change in its R&D programs

ASTM will stop enrollment and end the P3 REVIVE clinical trial in patients with critical limb ischemia (CLI).

ASTM will now also execute a corporate restructuring that will reduce staff and operating expenses by approximately 50%.

ASTM will begin treating patients in the P2b ixCELL-DCM clinical study within the next few weeks. The ixCELL-DCM trial is a randomized, double-blind, placebo-controlled Phase 2b study. Approximately 108 patients will be enrolled at about 30 sites in the U.S.

The Bottom Line: Focus shifted to dilated cardiomyopathy and stop enrollment and end P3 REVIVE CLI study following strategic program review. A restructuring will significantly reduce operating expenses and capital requirements. In an earlier P2a DCM clinical trial, ixmyelocel-T was well-tolerated and efficacy observations were consistent with improved function of impaired myocardium in patients with DCM.

ASTM closed at $1.15 and will get hammered today - so much for shareholder value as ASTM joins the crowded … multiple of companies focused on heart related disease. An extremely sad status … after all the CLI promises … 3 equity offerings and a preferred financing by MLV <Dart family>. Expect … blow back devastating the stock pricing! Do I see a $050 -$0.75 share pricing … SELL. Just when I thought a day off was due for the Easter holiday weekend … a lot more to follow …!

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You